Ovarian cancer is a challenging disease with a high mortality rate, emphasizing the need for effective diagnostic and prognostictools. Serum CA 125 levels have shown promise as a marker for ovarian cancer detection and monitoring. This retrospective study analyzesthe variations in CA 125 levels and their correlation with staging and histological subtypes in ovarian carcinoma patients. The study aims todetermine whether CA 125 levels correlate with ovarian cancer staging and histological subtypes. It is also an attempt to assess the changesin CA 125 levels before and after three cycles of neo-adjuvant chemotherapy and investigate the demographic characteristics of ovariancancer patients. This retrospective observational study analyses the case reports of 126 ovarian cancer patients diagnosed and treated at atertiary care cancer center in India. Patient demographic data, CA 125 levels before and after chemotherapy, histological types, and staginginformation were collected. Statistical analysis was performed using IBM SPSS. The analysis revealed that most patients were above 52 yearsold, married, and had children. Surface epithelial ovarian cancer was the most frequent histological type, with high-grade serous carcinomabeing the most common subtype. The majority of patients were diagnosed at advanced stages. CA 125 levels decreased after chemotherapy,but the difference was not statistically significant. Serum CA-125 levels hold value as a prognostic tool in ovarian cancer, aiding in diseasemonitoring and predicting progression. However, CA 125 levels alone may not be sufficient for determining treatment efficacy or prognosis.These findings contribute to our understanding of ovarian cancer and highlight the importance of monitoring CA 125 levels in assessingdisease prognosis and progression.

1. Hossain KR, Escobar Bermeo JD, Warton K, Valenzuela SM. New approaches and biomarkercandidates for the earlydetection of ovariancancer. Front Bioeng Biotechnol.2022;10:819183. doi: 10.3389/fbioe.2022.819183, PMID 35223789.
2. Jindal D, Sahasrabhojanee M, Jindal M, D’Souza J. Epidemiology of epithelial ovarian cancer: A tertiary hospital-based study in Goa, India. Int J Reprod Contracept Obstet Gynecol.2017;6(6):2541-6. doi: 10.18203/2320-1770.ijrcog20172348.
3. Blagden S, Abdel Mouti MA, Chettle J. Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer. Wiley Interdiscip Rev RNA. 2018;9(1):e1432. doi: 10.1002/wrna.1432, PMID 28762650.
4. Shabir S, Gill PK. Global scenario on ovarian cancer – its dynamics, relative survival, treatment, and epidemiology: Adesh Univ.J Med Sci Res.2020;2(1):17-25.
5. Murthy NS, Shalini S, Suman G, Pruthvish S, Mathew A. Changing trends in incidence of ovarian cancer - the Indian scenario. Asian Pac J Cancer Prev. 2009;10(6):1025-30. PMID 20192577.
6. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061. doi:10.1038/nrdp.2016.61, PMID 27558151.
7. Radziszewska AU, Karczmarek-Borowska B, Wójcik S, Kluz T. Survival rates among women with ovarian cancers diagnosed in the area of Podkarpacie province in the years 1990-2015. Contemp Oncol (Pozn). 2018;22(3):151-7. doi:10.5114/wo.2018.78935, PMID 30455586.
8. Elias KM, Guo J, Bast RCJr. Early detection of ovariancancer. Hematol Oncol Clin North Am.2018;32(6):903-14. doi:10.1016/j.hoc.2018.07.003, PMID 30390764.
9. Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med.2007;1(4):513-23. doi:10.2217/17520363.1.4.513, PMID 20477371.
10. Okunowo AA, Adaramoye VO. Women’s knowledge on ovariancancersymptoms and riskfactors in Nigeria: aninstitutional-based study. J Epidemiol Glob Health. 2018;8(1-2):34-41. doi:10.2991/j.jegh.2018.07.002, PMID 30859785.
11. ReinBJD, GuptaS, DadaR, SafiJ, MichenerC, AgarwalA. Potential markers for detection and monitoring of ovariancancer. J Oncol. 2011;2011, 17 pages:Article ID475983. doi: 10.1155/2011/475983, PMID 21577260.
12. Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-PrisnoDEet al.Worldwide burden, riskfactors, and temporaltrends of ovariancancer: A globalstudy. Cancers. 2022;14(9):2230. doi: 10.3390/cancers14092230, PMID 35565359.
13. Hu X, Zhang J, Cao Y. Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study. BMC Cancer. 2022;22(1):544. doi: 10.1186/s12885-022-09637-7, PMID 35568827.
14. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res.2019;12(1):28. doi: 10.1186/s13048-019-0503-7, PMID 30917847.
15. Davis HM, Zurawski VRJr, Bast RCJr, Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res. 1986;46(12 Pt 1):6143-8. PMID 2430690.
16. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993;71(2);Suppl:517-23. doi: 10.1002/cncr.2820710205, PMID 8420671.
17. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res.2009;2:13. doi: 10.1186/1757-2215-2-13, PMID 19818123.
18. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR.CA125 and ovariancancer: A comprehensivereview. Cancers. 2020;12(12):3730. doi: 10.3390/cancers12123730, PMID 33322519.
19. Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188503. doi: 10.1016/j.bbcan.2021.188503, PMID 33421585.
20. Tannenbaum SL, Zhao W, Koru-Sengul T, Miao F, Lee D, Byrne MM. Marital status and its effect on lung cancer survival. SpringerPlus. 2013;2:504. doi: 10.1186/2193-1801-2-504, PMID 25674396.
21. Smith AC, Johnson B, Anderson C. Ovarian cancer in postmenopausal women: incidence, risk factors, and therapeutic challenges. MenopauseJ. 2018;25(8):928-35. doi: 10.1097/GME.0000000000001126.
22. Lee HJ, Lee B, Choi H, Kim T, Kim Y, Kim YB. Impact of hormonereplacementtherapy on risk of ovariancancer in postmenopausalwomen with denovoendometriosis or a history of endometriosis. Cancers. 2023;15(6):1708. doi: 10.3390/cancers15061708, PMID 36980597.
23. Cheng HY, Zeng L, Ye X, Ma RQ, Tang ZJ, Chu HLet al.Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people. ChinMedJ (Engl). 2020;133(11):1285-91. doi: 10.1097/CM9.0000000000000785, PMID 32404690.
24. Pereira M, Matuszewska K, Jamieson C, Petrik J. Characterizing endocrinestatus, tumorhypoxia and immunogenicity for therapysuccess in epithelialovariancancer. Front Endocrinol. 2021;12:772349. doi: 10.3389/fendo.2021.772349, PMID 34867818.
25. McLemore MR, Miaskowski C, Aouizerat BE, Chen LM, Dodd MJ. Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs. 2009;32(4):281-8; quiz 289. doi: 10.1097/NCC.0b013e31819d30d6, PMID 19444085.
26. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287-99. doi: 10.2147/IJWH.S197604, PMID 31118829.
27. Pasvanis M, Hegarty S, Russell H, Peate M, Marino JL. Exploring the experiences and priorities of women with a diagnosis of ovarian cancer. Support Care Cancer. 2023;31(7):432. doi: 10.1007/s00520-023-07903-3, PMID 37389743.
28. KurmanRJ, ShihIeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol.2016;186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011, PMID 27012190.
29. Shoji T, Tatsuki S, Abe M, Tomabechi H, Takatori E, Kaido Y, et al.Novel therapeuticstrategies for refractoryovariancancers: clearcell and mucinouscarcinomas. Cancers. 2021;13(23):6120. doi: 10.3390/cancers13236120, PMID 34885229.
30. BristowRE, TomacruzRS, ArmstrongDK, TrimbleEL, MontzFJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol.2002;20(5):1248-59. doi: 10.1200/JCO.2002.20.5.1248, PMID 11870167.
31. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JKet al.Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016Mar5;387(10022):945-56. doi: 10.1016/S0140-6736(15)01224-6, PMID 26707054.
32. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer Ret al.An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J ClinOncol. 2007Feb10;25(5):517-25. doi: 10.1200/JCO.2006.06.3743, PMID 17290060.